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Abstract
Background: Predicting the aggressive behavior of non-functional pancreatic neuroendocrine tumors (NF-PNET)
remains controversial. We wanted to explore, in a prospective setting, whether the diagnostic accuracy can be
improved by dual-tracer functional imaging 68Ga-DOTANOC and 18F-FDG-PET/CT in patients with NF-PNETs.
Methods: Thirty-one patients with NF-PNET (90% asymptomatic) underwent PET-imaging with 18F-FDG and 68Ga-
DOTANOC, followed by surgery (n = 20), an endoscopic ultrasonography and fine-needle biopsy (n = 2) or follow-
up (n = 9). A focal activity on PET/CT greater than the background that could not be identified as physiological
activity was considered to indicate tumor tissue. The imaging results were compared to histopathology. The mean
follow-up time was 31.3 months.
Results: Thirty-one patients presented a total of 53 lesions (40 histologically confirmed) on PET/CT. Thirty patients
had a 68Ga-DOTANOC-positive tumor (sensitivity 97%) and 10 patients had an 18F-FDG-positive tumor. In addition,
one 68Ga-DOTANOC-negative patient was 18F-FDG-positive. 18F-FDG-PET/CT was positive in 19% (3/16) of the G1
tumors, 63% (5/8) of the G2 tumors and 1/1 of the well-differentiated G3 tumor. 68Ga-DOTANOC-PET/CT was
positive in 94% of the G1 tumors, 100% of the G2 tumors and 1/1 of the well-differentiated G3 tumor. Two out of
six (33%) of the patients with lymph node metastases (LN+) were 18F-FDG-positive. The 18F-FDG-PET/CT correlated
with tumor Ki-67 (P = 0.021). Further, the Krenning score correlated with tumor Ki-67 (P = 0.013). 18F-FDG-positive
tumors were significantly larger than the 18F-FDG-negative tumors (P = 0.012). 18F-FDG-PET/CT showed a positive
predictive value of 78% in the detection of potentially aggressive tumors (G2, G3, or LN + PNETs); the negative
predictive value was 69%.
Conclusions: 18F-FDG-PET/CT is useful to predict tumor grade but not the LN+ of NF-PNETs. Patients with 18F-FDG-
avid NF-PNETs should be referred for surgery. The 68Ga-DOTANOC-PET/CT also has prognostic value since the
Krenning score predicts the histopathological tumor grade.
Trial registration: The study has been registered at ClinicalTrials.gov; Non-functional Pancreatic NET and PET
imaging, NCT02621541.
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Background
Pancreatic neuroendocrine tumors (PNETs) constitute 3%
of all pancreatic neoplasms and 60–80% of PNETs are de-
fined as non-functional (NF-PNET) [1]. The incidence has
increased in recent years due to the expanding use of im-
aging [2]. Despite the generally indolent nature, it has been
recognized that the pathological potential of PNETs is highly
variable and some NF-PNETs present at an advanced stage
with local invasion and distant metastases [3, 4]. Heterogen-
eity of PNETs makes therapeutic decisions difficult with no
clear consensus.
The most powerful prognostic factors are the grade and
distant metastases [4]. Although complete surgical resection
is the only potentially curative treatment, a conservative
approach seems to be safe for asymptomatic and stable
sporadic NF-PNET≤ 2 cm [5, 6]. However, a locally
advanced disease with lymph node metastases (LN+) is rare
but also possible on small (1–2 cm) NF-PNETs [7]. In a
review of 136 surgical patients, Hashim and colleagues
suggested a metastatic rate of 8% in PNETs as small as 1.5
cm [8]. In a retrospective analysis (n = 181), Partelli et al.
[9] demonstrated that lymph node metastases decreased
the 5-year disease-free survival in NF-PNETs (70% vs 97%,
P < 0.001). Pancreatic resection is a high-risk operation
with 20–40% morbidity and 1–2% mortality [10, 11].
Knowing the risks of pancreatic surgery, it is challenging to
decide between surgery and follow-up for these patients.
The vast majority of well-differentiated PNETs express
somatostatin receptors (SSTRs) and can be visualized by
the binding of a radioactive somatostatin analog. SSTR-
based functional imaging, 68Ga-DOTANOC positron
emission tomography/computed tomography (PET/CT)
has a high diagnostic sensitivity (88–100%) for localizing
NETs [12–14] but provides limited information about
the aggressiveness of PNET. 18F-fluoro-2-deoxyglucose
(FDG)-PET/CT demonstrates increased cellular tissue
metabolism. Although the sensitivity of 18F-FDG-PET/
CT imaging is low for NETs, positive 18F-FDG-PET/CT
predicts poor survival for NET patients [15, 16]. Dual-
tracer functional imaging of NF-PNET has only been
studied in retrospective series [17, 18].
The aim of this study was to determine the role of dual-
tracer functional imaging in predicting aggressive behavior
in NF-PNETs in a prospective setting with histopatho-
logical references. The hypothesis was that the higher the
maximum standardized uptake value (SUVmax) of
18F-
FDG-PET/CT then the higher the Ki-67 of the tumor
would be and the higher the SUVmax of
68Ga-DOTA-
NOC-PET/CT the lower the Ki-67 of the tumor would be.
Materials and methods
Study design
The study was a prospective, multicenter clinical trial at
Turku and Helsinki University Hospitals in Finland.
From January 2016 to January 2018, a total of 35 patients
suspected of having NF-PNET on a primary CT were pro-
spectively imaged using 68Ga-DOTANOC-PET/CT and
18F-FDG-PET/CT. Four patients were excluded; one patient
diagnosed with a pancreatic adenocarcinoma, another with
a functional duodenal neuroendocrine tumor (gastrinoma),
one with mixed neuroendocrine non-neuroendocrine neo-
plasm and one patient with an uncertain diagnosis lacking
pathology. A total of 31 patients (age range 20-83 years;
mean age 60 ± 18 years) were enrolled in the study. Patient
characteristics are given in Table 1. Twenty patients were
operated. Four patients underwent endoscopic ultrasonog-
raphy and fine-needle biopsy (EUS-FNB), but two of these
were found to be non-specific. One patient with Von
Hippel-Lindau (VHL) syndrome had a pancreatic intrae-
pithelial neoplasia lesion in the histopathological analysis
and two NF-PNETs (Ø 13 and 10 mm on MRI) were
followed up. Twenty-two patients had a histopathological
confirmation (20 resection specimens and two EUS-FNB)
and nine patients with a positive 68Ga-DOTANOC PET/
CT finding were followed up (33.5 ± 6.2 months). Thirty-
one patients had a total of 53 lesions on the PET/CT im-
aging. The median PET/CT imaging interval was 34 days
(range 2–164, IQR 12–62 days) in 29 patients. The PET/
CT imaging interval was delayed in two patients, in 1 to
360 days due to logistical reasons and in another to 244
days due to a more urgent operation. Since there were two
methods to measure chromogranin A (CgA) in use at the
laboratories during the study period, the CgA was reported
as three subgroups. For an accurate diagnosis of PNETs
every attempt was made to establish a tissue sample by
means of an operation or an EUS-FNB. Follow-up time was
measured from the date of the first PET/CT scan to the re-
view time. Patients were treated in accordance with the
routine procedures of the departments and the European
Guidelines [19]. The study has been registered at Clinical
Trials.gov (NCT02621541).
68Ga-DOTANOC and 18F-FDG-PET/CT protocol
PET/CT was performed using the Discovery STE (6 68Ga-
DOTANOC and 14 18F-FDG-PET/CT) or VCT (11 68Ga-
DOTANOC and 10 18F-FDG-PET/CT) scanner (General
Electric Medical Systems, Milwaukee, WI) and one patient
underwent 18F-FDG-PET/(magnetic resonance imaging)
MRI using an Ingenuity TF PET/MRI scanner (Phillips
Medical Systems, Cleveland, OH) at Turku PET center
and Siemens Biograph mCT 64 (Siemens Healthineers,
Erlangen, Germany) (12 68Ga-DOTANOC and 4 18F-
FDG-PET/CT) or Gemini PET-CT scanner (Philips Inc,
USA) (1 68Ga-DOTANOC and 1 18F-FDG-PET/CT) at
Nuclear Medicine Department in Helsinki University Hos-
pital. One 68Ga-DOTANOC and 1 18F- FDG-PET/CT
scan were done at a private institute using the Siemens
Biograph 6 (Siemens Medical Solutions, USA).
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Patients underwent a whole-body PET/CT scan from the
level of the skull base to the mid-thigh starting 64 ± 13 min
after the injection of 68Ga-DOTANOC and 55 ± 9 min after
18F-FDG. The mean dose of intravenous 68Ga-DOTANOC
was 143.8 ± 17.1 MBq and 18F-FDG was 321.9 ± 67.3 MBq.
The patients fasted for 6 h before the study. Blood glucose
levels were checked before any 18F-FDG-PET/CT for pa-
tients with diabetes or previous history of glucocorticoids
use (range 4.6–8.3 mmol/l). A low-dose PET/CT was
followed with a whole-body diagnostic CT scan after auto-
mated intravenous injection of the contrast agent, either
with 68Ga-DOTANOC- or 18F-FDG-PET/CT. Attenuation
correction was performed using a low-dose ultrafast CT
protocol (80 mAs, 140 kV, 0.3 mSv per field of view). Images
were reconstructed full width at half maximum and fully
three-dimensional maximum-likelihood ordered-subset ex-
pectation maximization (OSEM). Data was corrected for
dead time, decay, and photon attenuation and was recon-
structed to a 128 × 128 matrix.
Data analysis
The diagnostic accuracy of the PET/CT studies was
assessed by comparing the PET-images and the histo-
pathological reports (n = 22). When proper histology
was not available (n=9), the consensus was based on the
sum of the laboratory tests and imaging procedures.
This information was used for the interpretation of the
lesion analysis (Figs. 1 and 2). Data on the primary
tumor site and the diameter were collected from the
pathology reports and from other imaging studies (con-
trast CT or MRI). The histopathological analysis was
blind and conducted by two experienced pathologist (J.A
and J.Su). Clinical TNM and grade classification was
based on the 2017 World Health Organization (WHO)
classification of PNETs [5].
Only the patients and the tumors with a histopatho-
logical confirmation were included in the correlation
analysis. Ki-67-labeling indexes were studied from the
whole series of tumors using MIB-I antibody (Dako,
Agilent Pathology Solutions, Santa Clara, CA, USA) and
automated staining instrument (BenchMark Ultra, Ven-
tana Medical Systems, Inc., Tucson, AZ, USA). All stain-
ings were prepared in the clinical pathology laboratory
(HUSLAB, Helsinki University Hospital) under standard-
ized conditions. Stained slides were digitized with a
Panoramic scanner (3DHISTECH, Budapest, Hungary)
and Ki-67 values were calculated by T.V from hot spot
areas comprising of at least 2000 cells. A publicly avail-
able application that was shown suitable for pancreatic
NETs, was used for quantitative image analysis (Immu-
noRatio) [20, 21].
Analyses of PET/CT-images were interpreted by a
dedicated nuclear medicine physician (J.K), with short
referral information but blinded to histopathological
Table 1 Patient characteristics
No. patients 31
Gender, Male, n (%) 20 (65)
Age years, mean (SD) 59.6 (17.6)
BMI, mean (SD) 26.3 (4.0)
Asymptomatic, n (%) 29 (90)
MEN1 syndrome, n (%) 7 (23)
CgA, n (%)
Strongly positive 3 (10)
Weakly positive 15 (48)
Negative 13 (42)
PP (pmol/L), median (IQR) 68 (41–129)
5-HIAA (nmol/L), median (IQR) 64 (53–64)
Primary tumor size (mm)
All patients, median (IQR) 24 (14–35)
Operated, median (IQR) (n = 20) 31 (20–52)
Biopsy and follow-up, median (min–max) (n = 2) 24 (22–25)
Follow-up*, median (IQR) (n = 9) 14 (13–21)
Tumor localization, n (%)
Head 12 (39)
Body 2 (6)
Tail 10 (32)
Multiple 7 (23)
Treatment, n (%)
Surgery 20 (65)
Biopsy and follow-up 2 (6)
Follow-up* 9 (29)
Type of surgery, n (%)
Total pancreatectomy 2 (10)
Pancreaticoduodenectomy 4 (20)
Distal pancreatectomy 13 (65)
Enucleation 1 (5)
Type of surgery, n (%)
Open 13 (75)
Laparoscopic 5 (25)
Robotic surgery 2 (10)
Grade, n (%)
G1 13 (59)
G2 8 (36)
G3 NET 1 (5)
G3 NEC 0
Abbreviations: CgA, circulating chromogranin A, strongly positive indicates S-
CgA = 13.5 nmol/L or P-CgA 9–37 nmol/L, weakly positive indicates S-CgA 2.2–
4.7 nmol/L or P-CgA 3.0–4.8 nmol/L and negative indicates S-CgA < 2.1 nmol/L
or P-CgA < 3.0 nmol/L; BMI, body mass index, kg/m2; MEN1, multiple
endocrine neoplasia type 1 syndrome; PP, pancreatic polypeptide; 5-HIAA,
5-hydroxyindoleatic acid
*Two patients underwent non-diagnostic EUS-FNB (endoscopic
ultrasonography and fine needle biopsy)
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report. The SUVmax–values were determined for every
tumor or abnormal anatomical region on both 68Ga-
DOTANOC and 18F-FDG-PET/CT. For the PET/CT-stud-
ies areas with a focal activity greater than the background
that could not be identified as physiological activity were
considered to indicate tumor tissue. Lesions were graded
on 68Ga-DOTANOC-PET/CT with the Krenning score, by
semi-quantitatively comparing SUVmax of the tumors to the
reference organs such as liver and spleen. Krenning scoring
was performed as follows: score 1: uptake < normal liver, 2:
uptake = normal liver, 3: uptake > normal liver and 4:
uptake > spleen or kidneys [22]. Further, by using the dual-
tracer PET/CT the NETPET-score (grades P1–5) was de-
fined. Grade P1 indicated purely somatostatin analog avid
lesion without 18F-FDG-uptake and P5 indicated the pres-
ence of a significant 18F-FDG-positive and somatostatin
Fig. 1 Characteristics of lesions detected on 68Ga-DOTANOC-PET/CT. TP, true-positive; FP, false-positive; TN, true-negative; FN, false negative; LN, lymph
node. †Diagnosis was made by biopsy, stage unknown. ‡Unknown lymph node status due to enucleation. §MEN1 patient, who underwent total
pancreatectomy: a total of 13 tumors (8 = G1, 5 = G2); 6 were detected on PET/CT (TP) and 7 were FN. ▲A 18F-FDG-avid G1 tumor with LN metastases
Fig. 2 Characteristics of lesions on 18F-FDG-PET/CT. TP, true-positive, G2, G3, lymph node metastasis (LN+) or distant metastasis (M+); FP, false-positive,
G1, no lymph node metastases (LN-) or no distant metastases (M-); TN, true-negative, : G1, LN- or M- ; FN, false negative, G2, G3, LN+ or M+. †MEN1
patient underwent total pancreatectomy: on histopathological report total of 13 tumors was detected: (8 = G1, 5 = G2); 1 was 18F-FDG-positive (1 TP),
and other 12 18F-FDG-negative (8 TN and 4 FN). ‡Diagnosis was made by biopsy, stage unknown. §Unknown LN status due to enucleation
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analog-negative diseas e[23]. The imaging analysis was per-
formed using ADW 4.4 workstation.
Statistical analysis
Normally distributed variables were expressed as means
and standard deviations (SD) variables not following a nor-
mal distribution as medians and interquartile ranges (IQR)
and categorical variables as frequencies and proportions.
The Shapiro-Wilk test was used to test deviations from a
normal distribution. Spearman’s rank correlation was used
to test the relationship between Ki-67 and SUVmax due to a
lack of normally distributed data. The Mann-Whitney or
the Kruskal-Wallis tests were used to discover the differ-
ences between the groups in continuous variables; Fisher’s
exact test was used for binary variables and the linear by
linear association test for ordinal variables. A P value of <
0.05 was considered statistically significant, and two-tailed
tests were used. The data analysis was performed using
commercially available software (Statistical Package for So-
cial Sciences, version 24, IBM Corp., Armonk, NY, USA).
Results
Features of NF-PNETs and histopathological grading
The type of surgery and histopathological finding of the
tumors are presented in Table 1. Patients with G1 NF-
PNET were more commonly asymptomatic (92%) com-
pared to G2 patients (75% asymptomatic), but the only
patient with a G3 tumor was also asymptomatic (P =
0.595). One symptomatic patient had jaundice and two
had upper abdominal pains. All the symptomatic pa-
tients had sporadic NF-PNET.
Multiple endocrine neoplasia 1 (MEN1) patients (n = 7)
more commonly had a G1 (71%) rather than a G2 (29%)
tumor and none had a G3 tumor, but the difference was
not statistically significant (P = 0.470). There was no cor-
relation between the tumor size and the grade: G1 (34 ±
27 mm), G2 (36 ± 28 mm), and G3 (n = 1, 45 mm) (P =
0.800). However, all the operated primary tumors ≤ 2 cm
(n = 6) were G1 tumors without lymph node metastases.
The most common location for the G1 tumor was the tail
of the pancreas (54%). Three out of eight (38%) of the G2
NF-PNETs were located in the head and the same
amount; 3/8 (38%) in the tail of the pancreas. The G3 NF-
PNET was located in the head of the pancreas. There was
no statistical significance between the location of a tumor
and the grade of a tumor (P = 0.554). There was a trend
between the grade and CgA (P = 0.108).
Correlation between 68Ga-DOTANOC-PET/CT and grade
68Ga-DOTANOC-PET/CT was positive in 30 patients
and thus the sensitivity of the 68Ga-DOTANOC-PET/CT
detecting of NF-PNETs was 97% and specificity was 100%.
The only 68Ga-DOTANOC-negative tumor (G1) was 18F-
FDG-positive and the patient had multiple (11/13) lymph
node metastases. Thirty-one study patients had a total of
53 lesions, 45 of these were 68Ga-DOTANOC-positive
(32/45 histologically confirmed lesions). Eight lesions were
not detected by PET/CT at all and were false negative
(FN) lesions (Fig. 1); one patient had negative 68Ga-
DOTANOC-PET/CT and histologically confirmed G1
NET and seven FN lesions were detected on the same
MEN1 patient who underwent a total pancreatectomy. He
had a total of 13 PNETs (five G2 T1N0 tumors and eight
G1 T1N0 tumors). Six of these lesions were detected on
68Ga-DOTANOC-PET/CT and one of these tumors was
also 18F-FDG-positive. Three lesions were > 10 mm and
10 were 5–10 mm in size. There were also multiple micro-
adenomas (NET< 5 mm). Due to several lesions, it was
impossible to combine the information concerning the 13
tumors on a histopathological report and the six lesions
on 68Ga-DOTANOC-PET/CT. Only the largest primary
tumor was included in the lesion analysis.
The lesion-based sensitivity of 68Ga-DOTANOC-PET/
CT to detect of NF-PNETs was 85% with a specificity of
100%. There was no correlation between the SUVmax of
68Ga-DOTANOC-PET/CT and the tumor Ki-67 (Spear-
mans’s ρ = 0.271, P = 0.190) (Fig. 3). We also analyzed the
Krenning and NETPET score of the lesions (Table 2).
There was a statistically significant correlation between
both Krenning score and Ki-67 (P = 0.013) and NETPET
score and Ki-67 (P = 0.036) (n = 43).
Correlation between 18F-FDG-PET/CT and grade
18F-FDG-PET/CT was positive for 11 of 31 patients
(35%) and the SUVmax ranged from 3.0 to 18.6 (median
4.5, IQR 3.4–8.7). Clinical characteristics of patients accord-
ing to 18F-FDG-uptake are summarized in Table 3 and le-
sion characteristics are detailed in Fig. 2. In the lesion based
analysis on 18F-FDG-PET/CT, 52 primary lesions were ana-
lyzed on 31 patients (Fig. 2). Three of the 18F-FDG-avid tu-
mors were G1 (two T3N0 Ø ≥ 9 cm and one T3N1), five
G2 (one T1N0, one T2N0, one T3N0, one T3N1 and one
patient assessed by EUS-FNB, too frail for surgery) and one
well-differentiated G3 (T3N0) tumor (Fig. 4). Two 18F-
FDG-positive tumors are intensively followed up without a
histological confirmation. 18F-FDG-PET/CT was positive in
19% (3/16) of G1 tumors, 63% (5/8) of G2 tumors and
100% (1/1) of G3 tumors. There was a statistically signifi-
cant positive correlation between 18F-FDG-uptake and the
tumor Ki-67 (Spearmans’s ρ = 0.458, P = 0.021) (Fig. 3).
When tumors were divided according to 18F-FDG-
positivity and 18F-FDG-negativity, the correlation with
the grade stayed significant (P = 0.023) (Table 3). 18F-
FDG-positive tumors were significantly larger than
18F-FDG-negative tumors, with a mean maximum
diameter of 46 mm (median 33, IQR 23–90 mm) com-
pared with 24 mm (median 20, IQR 12–30 mm; P = 0.012).
All the 18F-FDG-negative patients were asymptomatic and
Majala et al. EJNMMI Research           (2019) 9:116 Page 5 of 12
73% 18F-FDG-positive patients were asymptomatic (P =
0.037). The symptomatic patients had more intense 18F-
FDG-uptake than the asymptomatic patients (P = 0.003).
However, there was no significant correlation between
symptoms and grade (P = 0.595) or symptoms and Ki-67 (P
= 0.102). 18F-FDG-PET/CT showed a positive predictive
value (PPV) of 78% in the detection of potentially aggressive
tumors (G2, G3, LN + or M+ histologically confirmed
PNETs) and the negative predictive value (NPV) was 69%.
Local and distant metastases
Six patients had histopathologically confirmed lymph
node metastases (mean 4.8 ± 3.4 nodes). Three LN+ were
in patients with G1 NF-PNETs and three in patients with
G2 NF-PNETs. All the LN+ patients were asymptomatic
and sporadic. Two of these six patients with LN+ (33%)
had an 18F-FDG-positive tumor and four tumors with
LN+ were 18F-FDG-negative (67%). Thus, 18% (2/11) of
18F-FDG-patients had LN+ vs. 20% (4/20) of 18F-FDG-
negative patients had LN+ (Fig. 5). In patients with LN+,
the mean primary tumor size was 54 ± 25 mm (range 24–
90 mm). In five patients, preoperative 68Ga-DOTANOC-
PET/CT did not reveal LN metastases. One patient had
several LN metastases but 68Ga-DOTANOC-PET/CT
showed only one metastatic lesion. Two patients were di-
agnosed with a NF-PNET in the tail of the pancreas and
liver metastasis (T3N1M1/G2/Ki-67 10% and T2N1M1/
G2/Ki-67 3%). Liver resection is arranged for another pa-
tient but to another no liver resection was performed due
to progression of the disease.
Prognosis and PET outcome
During the mean follow-up of 31.3 ± 6.2 months, one
patient died (due to long-term surgical complications). He
had a 68Ga-DOTANOC-negative and 18F-FDG-positive G1
T3N1 tumor. No recurrence had been detected during the
follow-up time. One patient with 68Ga-DOTANOC-posi-
tive and 18F-FDG-negative primary tumor and liver metas-
tases underwent a laparoscopic distal pancreatectomy and
splenectomy. Histopathological analysis confirmed a G2
T3N1M1 tumor. Due to the progression of the disease no
liver resection was arranged and capecitabine and temozo-
lomide combination therapy and previously Lutetium-177-
octreotate therapy was performed. One MEN1 patient with
68Ga-DOTANOC-positive and 18F-FDG-negative primary
Table 2 Krenning and NETPET score of the lesions (n = 43)
Krenning score n (%)
1 1 (2)
2 4 (9)
3 24 (56)
4 14 (33)
NETPET score n (%)
P1 32 (75)
P2 8 (19)
P3 1 (2)
P4 1 (2)
P5 1 (2)
From 53 lesions, 43 were analyzed. Two microadenomas, 1 68Ga-DOTANOC-
positive lymph node, and 7 68Ga-DOTANOC-negative false negative lesions of
a patient with 13 NETs were not included to this analysis
Fig. 3 Logarithm variation of the relationship between the tumor Ki-67 and uptake of 68Ga-DOTANOC (black circles) and 18F-FDG (grey circles) for
every tumor
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tumor underwent distal pancreatectomy and splenectomy
and histological analysis revealed a G2 T2N1M1 tumor.
Currently, a liver resection is planned due to the residual
liver metastasis. One patient underwent robotic distal pan-
createctomy and splenectomy due to two sporadic T1N0
G1 tumors. Stable residual tumor at the body of the pan-
creas is followed up. Among the follow-up group the VHL
patient’s tumor has enlarged and uptake of 18F-FDG in-
creased and surgery is considered. No disease progression
has been detected in other patients belonging to the follow-
up group (9 patients, 11 lesions).
Discussion
To our knowledge, this is the first prospective study evalu-
ating the impact of combined 68Ga-DOTANOC and 18F-
FDG-PET/CT in predicting the aggressive behavior of NF-
PNET. There is some previous data of the dual-tracer
imaging with series of different gastroenteropancreatic neu-
roendocrine tumors [18, 24] and retrospective series of
PNETs [17, 25]. The main interest of this study was to
evaluate if the malignant potential of NF-PNETs could be
predicted with dual-tracer PET/CT imaging. We found that
there was a statistically significant positive correlation
between 18F-FDG-uptake and the proliferation index of the
tumor (P = 0.021). However, there was no negative correl-
ation between 68Ga-DOTANOC-uptake and the Ki-67-
index (P = 0.190). Both the Krenning score and NETPET
score correlated statistically significantly with the Ki-67. In
this patient cohort, the lower 68Ga-DOTANOC uptake,
expressed as SUVmax values, was not directly associated to
more aggressive phenotype unless the comparison was
made to physiological organ activity by using Krenning
score or combined to 18F-FDG-imaging in NETPET score.
We also studied the ability of the dual-tracer PET/CT to
assess LN+ but no effect was seen in order to enable a diag-
nosis of a local metastatic disease.
18F-FDG-PET/CT imaging has traditionally been used
to assess adenocarcinoma and poorly-differentiated G3
Table 3 Clinical, histopathological and metabolic features of NF-PNETs
18F-FDG-positive
SUVmax range 3.0–8.6
18F-FDG-negative
SUVmax range 0.8–3.2
P 68Ga-DOTANOC-positive
SUVmax range 8.7–104.7
68Ga-DOTANOC-negative
SUVmax 4.4
P
Sex 1.000 1.000
Male 7/11 (64) 13/20 (65) 19/30 1/1
Female 4/11 (36) 7/20 (35) 11/30 0/1
Age, years 67 (38–78) 68 (50–71) 1.000 66 (47–72) 70 0.903
Primary tumor size, mm 33 (23–90) 20 (13–30) 0.023 24 (14-38) 33 0.581
Asymptomatic 8/11 (73) 20/20 (100) 0.037 27/30 1/1 1.000
CgA 0.258 0.516
Strongly positive 2/11 (18) 1/20 (5) 3/30 0/1
Weakly positive 6/11 (55) 9/20 (45) 15/30 0/1
Negative 3/11 (27) 11/20 (50) 12/30 1/1
Location 0.630 1.000
Head 6/11 (55) 6/20 (30) 11/30 1/1
Body 0/11 (0) 2/20 (10) 2/30 0/1
Tail 3/11 (27) 7/20 (35) 10/30 0/1
Multifocal 2/11 (18) 5/20 (25) 7/30 0/1
Grade* 0.023 1.000
G1 3/9 (33) 13/16 (81) 15/24 1/1
G2 5/9 (56) 3/16 (19) 8/24 0/1
G3 1/9 (11) 0/16 (0) 1/24 0/1
Ki-67 4.0 (1.5–11.0) 2.0 (1.0–2.5) 0.051 2.0 (1.0–4.5) 1.0 0.384
68Ga-DOTANOC-positive 10/11 (91%) 20/20 (100%) 0.355
18FDG-positive 10/30 (33%) 1/1 (100%) 0.355
LN+‰ 2/8 (33) 4/11 (36) 1.000 5/30 1/1 0.316
Categorical variables are expressed as n (%) and continuous variables are reported as median values (IQR)
Abbreviations: CgA, circulating chromogranin A, Strongly positive indicates S-CgA = 13.5 nmol/L or P-CgA 9–37 nmol/L, weakly positive indicates S-CgA 2.2–4.7
nmol/L or P-CgA 3.0–4.8 nmol/L and negative indicates S-CgA < 2.1 nmol/L or P-CgA < 3.0 nmol/L; LN+, lymph node metastases
*Lesion analysis (histologically confirmed, n = 25)
‰Follow-up patients, biopsied patients and one patient who underwent enucleation were excluded because it was not possible to assess their LN+
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Fig. 4 An 80-year-old male patient had a 3 cm solid mass in the head of the atrophic pancreas on CT (a). 68Ga-DOTANOC-PET/CT (b) showed
intense uptake (SUVmax 79 g/ml) and
18F-FDG-PET/CT (c) was positive (SUVmax 3.4 g/ml, higher than liver background). He underwent a
pancreaticoduodenectomy and histopathological analysis revealed a well-differentiated G3 PNET (Ki-67 31 %) (d, image magnification × 40)
without lymph node metastases
Fig. 5 A 32-year-old female patient had a 10 cm complex cystic-solid mass in the tail of the pancreas on CT (a). 68Ga-DOTANOC-PET/CT (b)
showed two different uptake intensity areas around a large cystic component (SUVmax 29 g/ml and 10.6 g/ml) in the pancreatic tumor.
18F-FDG-
PET/CT (c) was negative (SUVmax 3.2 g/ml). She underwent a distal pancreatectomy and splenectomy and histopathological analysis revealed a G1
PNET (Ki-67 < 2%) (d, image magnification × 40) with five lymph node metastases
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neuroendocrine carcinomas (NECs). However, recent data
has shown that 18F-FDG-PET/CT has prognostic value in
patients with well-differentiated NET, showing that high
uptake is associated with increased risk of early progression
[5, 26]. In retrospective series the prognostic value of 18F-
FDG-PET/CT imaging was even more powerful than the
grade of the tumor [15, 16]. A study by Chan et al. [23] of
62 metastatic NET patients combined the results of
somatostatin analogue and 18F-FDG-PET/CT to obtain an
imaging biomarker, a NETPET-score (grades P1–5), and a
classification system reflecting the burden of the disease.
Grade P1 indicated purely somatostatin analogue avid
lesion without 18F-FDG-uptake and P5 indicated the pres-
ence of a significant 18F-FDG-positive and somatostatin
analogue-negative disease. The NETPET-score correlated
positively with the histopathological grade and offered a
better prediction of overall survival. In concordance with
this we found a positive correlation between the NETPET
score and the proliferation index. Further there was a cor-
relation between the SUVmax of
18F-FDG-PET/CT and the
proliferation index, and this correlation maintained signifi-
cance when the patients were divided into WHO grades by
Ki-67. Sharma et al. [27] concluded that SUVmax on
68Ga-
DOTANOC-PET/CT was an independent, positive prog-
nostic factor in patients with well-differentiated NET in a
two-year median follow-up time. However, in light of this
observation, we did not find significant prognostic role for
68Ga-DOTANOC-uptake in our study due to short follow-
up time.
SSTR-based functional imaging with 68Ga-labelled pep-
tides, 68Ga-DOTATATE, 68Ga-DOTATOC, and 68Ga-
DOTANOC, has recently become the gold standard in the
diagnosis of the NETs due to better sensitivity compared
to 111In-DTPA-octreotide (Octreoscan®) [28] and lower
patient radiation and higher spatial resolution than
SPECT/CT [29]. 68Ga-DOTATATE has the strongest
SSTR2-binding affinity. However, 68Ga-DOTATOC and
especially 68Ga-DOTANOC have wider affinity profiles,
including SSTR2, SSTR3 and SSTR5. The three analogs
have shown no differences in clinical practice.
The sensitivity of the 68Ga-DOTANOC PET/CT for
detecting NF-PNETs is high and SSTR-based imaging is
a mandatory procedure to guide treatment planning
[30]. In our series, the sensitivity was 97% and the smal-
lest 68Ga-DOTANOC-avid and histologically confirmed
tumor was 6 mm. Lesion-based analysis sensitivity was
85% (45/53). Seven FN lesions occurred in the same
MEN1 patient who had a total of 13 PNETs (smallest 5–
10 mm in size) in the histopathological analysis. The fact
that not all of these multiple lesions of this MEN1 pa-
tient were detected with the 68Ga-DOTANOC should
not be considered a diagnostic failure.
The prognostic value of 18F-FDG-PET/CT in func-
tional imaging of NETs has been a target for recent
research. Garin et al. [24] investigated prospectively
well-differentiated metastatic NETs and reported that
18F-FDG-positivity correlated with decreased progression
free survival and overall survival. Cingarlini et al. [17]
compared retrospectively G1 and G2 PNETs and con-
cluded that 18F-FDG-PET/CT was positive in a smaller
proportion of G1 tumors (20%) compared with G2
tumors (76%). In our study 34% NF-PNET patients had
a positive 18F-FDG-PET/CT and the 18F-FDG-PET/CT
showed a PPV of 78% in the detection of potentially
aggressive tumors (G2, G3, LN+ or M+ PNETs), and the
NPV was 69%. 18F-FDG-PET/CT should have some rele-
vance when treatment options are discussed but the pos-
sibility of false imaging findings, especially false negative,
should be kept in mind. In this prospective study there
was a statistically significant correlation between the
SUVmax of
18F-FDG-PET/CT and the Ki-67 of the
primary tumor.
In the diagnostic workup of NF-PNETs, an endoscopic
ultrasonography-guided fine-needle aspiration (EUS-FNA)
could be an option, but it does not necessarily represent
the whole tumor in terms of aggressiveness and the tissue
material may be insufficient. In the French study [31], 30%
of tumor grading was up-scaled on the resected tissue.
Additionally, the heterogeneity in the tumor tissue may
interfere the assessment of Ki-67-labeling [32]. However,
in the prospective, multicenter, randomized controlled
trial the EUS-FNB, which also was used in our study, pro-
duced a more accurate diagnosis than EUS-FNA [33].
Boninsegna et al. [34] found that Ki-67 > 5% and the
ratio between the number of metastatic LNs above that
of the examined LNs were better predictors of the recur-
rence than tumor size. Further, in our series there was
no correlation between the tumor size and Ki-67-index,
but the 18F-FDG-positive tumors were significantly lar-
ger than the 18F-FDG-negative tumors.
Our study results show that dual-tracer PET/CT imaging
has a complementary role and it enables the detection of a
potentially aggressive disease during the diagnostic work-
up on well-differentiated NF-PNETs. Due to this we rec-
ommend 18F-FDG-PET/CT to be a part of a systematic
diagnostic work-up of asymptomatic NF-PNETs. Especially
if a consensus regarding surgical therapy cannot be
reached, dual-tracer PET/CT could supplement the evalu-
ation of the nature of the tumor. Due to our results 18F-
FDG-avid tumors should be considered for surgery if there
are no contraindications. In a case of a 18F-FDG-negative
lesion follow-up could be considered if all the other aspects
of the diagnostic work-up also support this treatment
strategy.
The strengths of the present study were histopatho-
logical re-evaluation of all the tumors as well as the im-
munohistochemical Ki-67 staining and automated image
analysis. The major limitation of the present study is the
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small number of patients, as the disease is rare. In
addition, the lack of histopathological confirmation of the
follow-up patients limits the analysis. For this subgroup of
patients, the collection of samples was not technically or
ethically feasible. However, the correlation analyses were
performed with histopathologically confirmed cases. Since
pancreatic neuroendocrine carcinomas are rare, the study
population consists of well-differentiated PNETs, which
impairs the sensitivity and specificity of 18F-FDG-PET/CT
to detect potentially aggressive tumors. In two patients the
interval between PET imaging was delayed (244 and 360
d), however, due to the indolent nature of NF-PNETs the
long dual PET/CT interval is likely to be of no great im-
portance and we preferred not to exclude these patients.
Another limitation is the relatively short follow-up time
(mean 31.3 mo, SD 6.2 mo) which is insufficient to esti-
mate a definitive prognosis. There is a possibility that dur-
ing a longer follow-up time the 18F-FDG-positive tumors
in this study would prove to be progressive, and our intent
is to analyze long time prognosis. In addition, it would be
essential to detect which biological and immunohisto-
chemical features are common for these tumors.
Conclusion
SUVmax measured on
18F-FDG-PET/CT was significantly
associated with the proliferation index, Ki-67, and will
serve as a surrogate measure of tumor aggressiveness in
patients with asymptomatic NF-PNET. Further, the
68Ga-DOTANOC-PET/CT has notable prognostic value
since the Krenning score predicts the histopathological
tumor grade.
To conclude, we recommend 18F-FDG-PET/CT to be a
part of a systematic diagnostic work-up of asymptomatic
NF-PNETs. This prospective study shows that dual-tracer
PET/CT imaging, using 18Ga-DOTANOC and 18F-FDG,
has a complementary role and it enables the detection of a
potentially aggressive disease during the diagnostic work-
up on well-differentiated NF-PNETs.
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